Cue Biopharma shares surge 10.27% intraday on positive Phase 1/2 study data for CUE-101 in HPV-positive cancers.

Cue Biopharma surged 10.27% intraday following the release of early Phase 1/2 trial data for its CUE-101 immunotherapy candidate, which showed promise in activating T-cells against HPV-positive head and neck cancers without excessive immune system activation. The news, reported by Bloomberg and Reuters, highlighted the therapy’s potential to differentiate from traditional checkpoint inhibitors, reigniting speculative investor optimism. While the article also noted ongoing cash burn, dilution risks, and skepticism about the company’s financial sustainability, the immediate price reaction was driven by the clinical progress. Analysts from B. Riley Securities and other boutiques reiterated bullish views, emphasizing the platform’s potential despite broader market caution. The intraday rally reflects a short-term focus on the positive data, overshadowing longer-term concerns about funding and pipeline risks.